Cases of allergic reactions in Moderna, Pfizer vaccines to be studied in US

The U.S. National Institutes of Health said on Wednesday that a mid-stage study to determine the risk of allergic reactions to Moderna Inc and Pfizer Inc COVID-19 vaccines has already begun from its side.

The U.S. reported several cases of an allergic reaction including serious episodes, known as anaphylaxis after vaccinations of Pfizer/BioNTech and Moderna shots.

The U.S. Centers for Disease Control and Prevention reported in January that allergic reactions are occurring at a rate of 11.1 per 1 million vaccinations.

National Institute of Allergy and Infectious Diseases will fund a study enrolling 3,400 adults between the ages of 18 to 69. About 60% of participants having a history of severe allergic reactions to food, insect stings, or immunotherapy will be included in the study.

The trial aims to record the proportion of participants who experience systemic allergic reactions within 90 minutes after injection.

The agency anticipates reporting data later this summer.